SCHEMBL322794

SCHEMBL322794

CN(C)C(=O)CCC(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 5/20 0.64
KDM2A Q9Y2K7 5/20 0.64
EGLN1 Q9GZT9 5/20 0.53
LMNA P02545 3/20 0.53
ALKBH5 Q6P6C2 1/20 0.53
SUCNR1 Q9BXA5 1/20 0.53
ALDH1A1 P00352 1/20 0.52
KDM5C P41229 3/20 0.48
KDM6B O15054 2/20 0.48
KDM7A Q6ZMT4 1/20 0.48
SLC15A2 Q16348 1/20 0.48
KDM4A O75164 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
FFAR3 O14843 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1375668 0.97 PHF8 (0.61) PHF8KDM2AEGLN1LMNAALKBH5
Dimethylamine SCHEMBL8787992 0.92 PHF8 (0.56) PHF8KDM2AEGLN1LMNAALKBH5
SCHEMBL1191256 0.87 ALDH1A1 (0.63) PHF8KDM2ALMNAALDH1A1KDM4A
SCHEMBL812501 0.83 ALDH1A1 (0.61) LMNAALDH1A1CHRNB2CHRNB4CHRNA4
SCHEMBL6688889 0.83 ALDH1A1 (0.61) PHF8KDM2ALMNAALDH1A1CHRNB2
SCHEMBL4815884 0.81 TSHR (0.60) PHF8KDM2ALMNAALDH1A1KDM7A
SCHEMBL20993533 0.81 TSHR (0.60) PHF8KDM2ALMNAALDH1A1KDM7A
SCHEMBL21703159 0.81 TSHR (0.60) PHF8KDM2ALMNAALDH1A1KDM7A
Succinic Acid SCHEMBL5875148 0.81 EGLN1 (0.69) PHF8KDM2AEGLN1LMNAALKBH5
Succinic Acid SCHEMBL5875155 0.81 EGLN1 (0.69) PHF8KDM2AEGLN1LMNAALKBH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 WO claimed
WO-2025126110-A1 ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES iTeos Belgium SA (BE) 2025-06-19 WO claimed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 WO claimed
CN-114555594-B Substituted azacycles as TRMP modulators 奇华顿股份有限公司 2025-03-18 CN claimed
CN-119143631-A Deprotection method for peptide compound or amide compound and resin removal method in solid phase reaction and method for producing peptide compound 中外制药株式会社 2024-12-17 CN claimed
CN-118290294-A Mg (magnesium)2+、Ca2+Recognition ligand and selective electrode as well as preparation method and application thereof 华东师范大学 2024-07-05 CN claimed
EP-3494104-B1 WARMING SENSATION COMPOUNDS TAKASAGO PERFUMERY CO LTD (JP) 2023-11-15 EP claimed
CN-116535365-A Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-08-04 CN claimed
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 US claimed
EP-4132933-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-02-15 EP claimed
EP-0962464-A2 Methods and compositions for detecting binding of ligand pair using non-fluorescent label Rapigene, Inc. (US) 1999-12-08 EP claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 WO claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 EP claimed
US-5730996-A Intercalates and expoliates formed with organic pesticide compounds and compositions containing the same AMCOL INTERNATIONAL CORPORATION (US) 1998-03-24 US claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
EP-0425650-B1 ANTI-INFLAMMATORY 4-AMINOPHENOL DERIVATIVES FISONS PLC (GB) 1995-08-09 EP claimed
EP-0515140-A1 Amide esters of rapamycin AMERICAN HOME PRODUCTS CORPORATION (US) 1992-11-25 EP claimed
US-5118677-A For treating transplant rejection, host vs. draft disease, autoimmune diseases and inflammations; antibody inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 1992-06-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD1, SLC29A1, ENTPD5 PHF8 4770/4885KDM2A 3263/4885EGLN1 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.